Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.